Sequenom licenses worldwide rights to develop age-related macular degeneration diagnostic test

Sequenom licenses worldwide rights to develop age-related macular degeneration diagnostic test

 

SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ — Sequenom, Inc. (NASDAQ: SQNM), today announced an exclusive worldwide licensing agreement with Optherion, Inc. Under the agreement, Sequenom’s CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM), obtained the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age- related macular degeneration (AMD).

Sequenom licenses worldwide rights to develop age-related macular degeneration diagnostic test

Sequenom, Inc. (NASDAQ: SQNM), today announced an exclusive worldwide licensing agreement with Optherion, Inc. Under the agreement, Sequenom’s CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM), obtained the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age- related macular degeneration (AMD).

Optherion completes $37 million start up financing

Optherion, Inc., a company developing products to diagnose and treat dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system, announced today that it has raised $37 million in start up financing.